The higher systemic clearance of some CYP3A4 (whether also P-gp) drug substrates in women vs. men is attributed in part to a higher hepatic CYP3A4 content in women. This, combined with the general paucity of reported sex differences in the apparent oral clearance of CYP3A4 substrates suggested a sex-dependent expression of CYP3A4 in the intestine but in a pattern opposite to the liver. Accordingly, duodenal biopsies obtained from healthy men (n=46) and women (n=45) were analyzed, by Western blot, for relative CYP3A4, as well as for CYP3A5 and P-gp, expression levels. Among all subjects, CYP3A4 and P-gp varied 8-and 10-fold, respectively. CYP3A5, which was readily detected in 27% of these predominantly Caucasian individuals, varied 7-fold. For all 3 proteins, a sex difference was not detected (p≥0.55). The lack of a difference remained for CYP3A4 and P-gp when the analysis was restricted to Caucasians (n=74) or to individuals with undetectable CYP3A5. Comparing the 21 premenopausal women (all were aged <45 years) with the 43 men aged <45 years, again no sex differences were detected in CYP3A4 and P-gp. Comparing the pre-with post-menopausal women, mean CYP3A4 content was 20% lower in the post-menopausal individuals (p=0.01).
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INTRODUCTION
In 1993, to ensure adequate representation of women in all phases of clinical drug trials, the FDA revised earlier (1977) guidelines to allow the inclusion of women of childbearing potential in phase I and early phase II studies (Merkatz et al., 1993) . In addition, because inclusion alone of both women and men would be insufficient to assess potential sex differences 1 in drug response, the earlier guidelines were further revised to request an assessment, among others, of potential pharmacokinetic differences between the sexes (Merkatz et al., 1993) . Consequently, sex-related effects on pharmacokinetics have gained considerable attention over the past decade. Such differences in the pharmacokinetics of a number of drugs have been described in several recent reviews (Cummins et al., 2002; Meibohm et al., 2002; Schwartz, 2003; Gandhi et al., 2004) . Although some differences can be explained by physiologic disparities between men and women (e.g., body weight, percent body fat, glomerular filtration rate, gastric motility), biochemical disparities may also exist (Meibohm et al., 2002) .
Metabolism by the liver represents the most common biochemical means of drug elimination. A superfamily of enzymes prominently involved in drug metabolism is the cytochromes P450 (CYPs). Of the numerous isoforms, CYP3A4 is one of the most important, as it constitutes a major portion (~30% on average) of total hepatic CYP content and is involved in the metabolism of >50% of drugs on the market (Thummel and Wilkinson, 1998) . Hepatic metabolism also frequently represents the major component of total systemic clearance. Many drugs that are substrates for CYP3A4 have shown, with intravenous dosing, a higher clearance in women compared to men, even after correcting for body weight (e.g., cyclosporine, erythromycin, methylprednisolone, tacrolimus, tirilazad, verapamil) (Cummins et al., 2002) .
This suggested that hepatic CYP3A4 activity might be higher in women compared to men.
Another biochemical component that can contribute to hepatic drug clearance is the
This article has not been copyedited and formatted. The final version may differ from this version. widely studied efflux transporter P-glycoprotein (P-gp), the product of the multidrug resistance gene 1 (MDR1 or ABCB1) (Ayrton and Morgan, 2001 ). Due to its canalicular location, P-gp functions to enhance the biliary excretion of its substrates, many of which are also substrates for CYP3A4 (e.g., those aforementioned). A sex difference in hepatic P-gp could therefore represent an additional determinant of sex-dependent differences in the hepatic clearance of dual CYP3A4/P-gp substrates. Moreover, based on results with a small number of healthy liver specimens, some investigators have proposed that P-gp expression in men might be greater than that in women (i.e., a pattern opposite to that for CYP3A4) (Schuetz et al., 1995; Cummins et al., 2002) .
To investigate sex differences in hepatic CYP3A4 and P-gp expression, Wolbold et al. (2003) analyzed 94 normal liver specimens obtained from a well-characterized group of patients undergoing hepatic surgery. The median CYP3A4 immunoreactive protein content in specimens obtained from women (n=46) was significantly greater, by 2.4-fold, than that in specimens obtained from men. This difference was not explained by preferential induction in women by concomitant medications because when the subset of specimens from individuals not taking medications (before surgery) was analyzed (23 men, 16 women), not only did the difference remain, it was more pronounced (3.1-fold) (Wolbold et al., 2003) . In contrast to CYP3A4, a sex difference in P-gp expression was not detected. Collectively, these results indicated that a sex difference in hepatic CYP3A4, but not P-gp, underlies sex-related differences in the systemic clearance of some CYP3A4 substrates.
In addition to the liver, CYP3A4 and P-gp are expressed in relatively high levels in epithelial cells lining the small intestinal mucosa (enterocytes). While the existence of sex differences in CYP3A4 and P-gp has been carefully investigated in the liver, the question remains whether such differences exist in the upper small intestine, the major site of drug absorption. It cannot be assumed that the findings reported for the liver will be the same in the intestine, since both CYP3A4 and P-gp appear to be regulated by different mechanisms in the DMD #2469 two organs, as evidenced by a lack of an intra-subject correlation between hepatic and intestinal CYP3A4 (Lown et al., 1994; Paine et al., 1997; von Richter et al., 2004) and P-gp (von Richter et al., 2004) . In addition, sex differences in the apparent oral clearance of CYP3A4 substrates, whether also P-gp substrates, have not been consistently reported (unlike with systemic clearance) (Cummins et al., 2002) . A sex difference in CYP3A4 expression may exist in the intestine, but in a pattern opposite to that in the liver (i.e., men > women). Indeed, Cummins et al. (2002) implied that such reverse patterns of sex-specific expression in liver and intestine would "cancel each other", thereby resulting in no net difference in oral clearance. To test this hypothesis, we analyzed 93 duodenal biopsy specimens, obtained from approximately equal numbers of healthy men and women, for CYP3A4 relative protein content. Relative CYP3A5 protein and P-gp contents were also determined. To our knowledge, this is the first report to address whether sex differences exist in CYP3A4, CYP3A5, and P-gp content in the proximal small intestine.
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MATERIALS AND METHODS
Materials and Chemicals
Sodium dodecyl sulfate, acrylamide/bis (37.5:1), ammonium persulfate, and TEMED were purchased from Bio-Rad (Hercules, CA). Polyvinylidene difluoride (PVDF) membrane (Hybond-P) and enhanced chemiluminescence reagents were purchased from Amersham Biosciences, Inc. (Piscataway, NJ). cDNA-expressed CYP3A4 and CYP3A5 and the anti-CYP3A4 and -CYP3A5 antibodies (WB-3A4 and -3A5, respectively) were purchased from BD Gentest (Woburn, MA). WB-3A4 and -3A5 were confirmed to not cross-react with CYP3A5 and CYP3A4, respectively, using the cDNA-expressed enzymes as reference standards (not shown). Homogenate prepared from the human intestinal cell line Caco-2, known to constitutively express relatively high levels of P-gp and villin, was from a previous study (Paine et al., 2002) . A murine monoclonal antibody raised against human villin was purchased from
Chemicon International (Temecula, CA). A rabbit polyclonal antibody raised against a peptide of human P-gp was a kind gift from Dr. Erin G. Schuetz (St. Jude's Children's Research Hospital, Memphis, TN). The secondary antibodies, rabbit anti-mouse and goat anti-rabbit horseradish peroxidase-conjugated IgG, were purchased from Zymed Laboratories (South San Francisco, CA). All other reagents were of electrophoresis grade.
Human Duodenal Biopsy Specimens
Duodenal pinch biopsies were previously obtained, by upper intestinal endoscopy, from 93 healthy volunteers (45 women), each of whom participated in 1 of 5 clinical studies from
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CYP3A4 and/or P-gp content. Study E investigated whether intestinal and/or hepatic CYP3A4 predicted estrogen levels in post-menopausal women about to undergo hormone replacement therapy (DK Turgeon and PB Watkins, unpublished data). Only 4 of the subjects (2 women)
were smokers. The men ranged in age from 19 to 49 years (mean, 28 years), and the women from 18 to 64 years (mean, 41 years).
Because the biopsy specimens were collected between 8 and 12 years ago, there was concern that the proteins of interest had degraded with time. Such effects were believed to be minimal, as all of the specimens had been stored at -80°C since their time of collection (except for an overnight transfer -on dry ice -from the University of Michigan to the University of North Carolina), and only material from unopened vials was used. To substantiate this notion, relatively "new" biopsy specimens obtained from 8 healthy men and 12 healthy women (SJ Mouly and PB Watkins, unpublished data) -and from unopened vials -were recently analyzed using the same methodology as for the "old" specimens. The median (range) of the relative Pgp, CYP3A4, and CYP3A5 contents for the new specimens were comparable to the old specimens, indicating minimal or no degradation after longer term storage.
Importantly, only those biopsies obtained under baseline conditions (i.e., before any treatment was initiated) were analyzed for the proteins of interest villin, CYP3A4, CYP3A5) . That is, none of the subjects were taking medications or supplements known to induce or inhibit CYP3A or P-gp, and none of the post-menopausal women were on hormone replacement therapy at the time such biopsies were collected.
For the endoscopic procedure, briefly, after a 4-hour fast, the subject was sedated with intravenous midazolam (Roche Pharmaceuticals, Nutley, NJ) and meperidine (Sanofi Winthrop, New York), and a fiberoptic endoscope was passed into the second portion of the duodenum, Lowry (1951) and were similar to those measured at the time the biopsies were originally obtained.
Western Blot Analysis
Preparation of Reference Standards and Control Specimens. In a pinch biopsy taken from the intestinal mucosa, the specific content of the protein of interest could vary with the depth of the biopsy (i.e., the deeper the biopsy, the lower the proportion of enterocytes, the lower the specific content) (Lown et al., 1994) . Therefore, our goal was to obtain relative expression levels, rather than specific contents, of the proteins of interest. As has been previously validated (Lown et al., 1994) , the constitutive, cytoskeletal protein villin was used as a control protein to correct for biopsy depth. In addition, because it was not technically feasible to analyze all 93 specimens on one day, and in triplicate, 'reference standards' and 'control specimens' were used to allow for day-to-day and blot-to-blot comparisons, respectively.
To minimize inter-and intra-day variations, all reference standards and controls were prepared at one time and stored at -80°C until use. For the reference standards, the 20 biopsy specimens from the recent clinical study described above (SJ Mouly and PB Watkins, unpublished data) were pooled and supplemented with Caco-2 cell homogenate (to maximize P-gp and villin concentrations) and cDNA-expressed CYP3A4 and CYP3A5 (to maximize CYP3A4 and CYP3A5 concentrations), then divided into aliquots (~200 µ L each). Total protein concentrations were determined by the method of Lowry (1951) , and each aliquot was diluted with sample buffer (2% sodium dodecyl sulfate, 5% sucrose, 5% 2-mercaptoethanol, 50 mM To monitor the status of protein migration during electrophoresis, the red dye Pyronin-Y (4 µL of 0.125%) was added to all reference standards and control specimens.
Protocol. On a given day, 3 sets of reference standards and 3 aliquots of the control specimen were retrieved from -80°C and allowed to thaw on ice. Thereafter, a maximum of 12
specimens from a single clinical study were diluted in sample buffer (to 30
volumes sufficient for three gels (~200 µ L each); to avoid a potential sex bias with studies E (100% women) and M (95% men), 3-4 specimens from one study were swapped with 3-4 specimens from the other study. Caco-2 homogenate and cDNA-expressed human CYP3A5
were diluted similarly to yield 30 µ g/60 µ L and 300 fmol/60 µL, respectively. The Caco-2 homogenate was used as a positive control for the detection of P-gp and villin; cDNAexpressed CYP3A5 was used as a positive control for the detection of CYP3A5. As with the reference standards and control specimens, Pyronin-Y was added to the study specimens, Caco-2 homogenate, and cDNA-expressed CYP3A5.
Four 15-well gels were prepared, each consisting of a 0.1% SDS-7% polyacrylamide separating gel and a 0.1% SDS-3% polyacrylamide stacking gel. The study specimens, control specimen, Caco-2 cell homogenate, and cDNA-expressed CYP3A5 were loaded (60 µL each) onto 3 of the gels. The 3 sets of reference standards (5 standards/set) were loaded onto the fourth gel. The proteins were electrophoretically separated over ~3.5 hours (i.e., when the dye front reached the bottom of the gel) using a Hoefer SE 600 vertical unit (Amersham). The proteins were then transferred to the PVDF membranes overnight at 4°C (~30 V) using a that contained the study and control specimens, Caco-2 homogenate, and cDNA-expressed CYP3A5.
To substantiate the average relative P-gp and CYP3A4 protein contents obtained with the 93 individual specimens, all specimens obtained from the men were pooled, and all specimens from the women were pooled. The total protein concentration of each pooled homogenate was determined by the method of Lowry (1951) , then diluted to 30
Pyronin-Y added in the same manner as described for the individual specimens. Each homogenate was loaded, in triplicate, onto a single 15-well gel. Because only 1 gel was needed to determine relative P-gp and CYP3A4 contents, reference standards and a control specimen were not used. The gels were transferred to PVDF membranes in the same manner as described for the individual specimens.
To substantiate the average relative CYP3A5 protein contents obtained with the 25 specimens containing readily detectable CYP3A5, each specimen was diluted to a concentration of 30 µ g/60 µ L, and Pyronin-Y added, in the same manner as described for the individual specimens. Because only 2 gels were needed to determine relative CYP3A5 contents, 1 of the specimens was loaded onto both gels to serve as a between-blot comparator, and no reference standards were used. The gels were transferred to PVDF membranes as described for the individual specimens.
Immunoblot Development.
For the 93 individual specimens, each of the 3 immunoblots containing the study specimens was placed, along with a reference strip, into 3 separate pans. The blots in each pan were developed simultaneously for the proteins of interest. First, the blots were blocked with 5% nonfat dry milk in PBS containing 0.3% Tween 20 (PBS-T). After 1 hour, the blots were rinsed in PBS-T, incubated with the anti-P-gp antibody
(1:10,000 in PBS-T) for 2 hours, rinsed in PBS-T, then incubated with the goat anti-rabbit secondary antibody (1:1000). After 2 hours, the blots were rinsed, then visualized for P-gp by enhanced chemiluminescence using the Chemi-Doc imaging system (Bio-Rad). The blots were
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(1:3000). After 1 hour, the blots were rinsed, incubated with the anti-CYP3A4 antibody (1:500) for 1 hour, rinsed, incubated with the goat anti-rabbit secondary antibody (1:500) for 1 hour, rinsed, then visualized simultaneously for villin and CYP3A4 by enhanced chemiluminescence.
Preliminary studies indicated that this order of development with the various primary antibodies allowed the use of the same immunoblot for the visualization of the 4 proteins of interest with the least background.
The 1 immunoblot containing the 2 pooled homogenates was developed for P-gp, then for villin and CYP3A4 as described above for the individual specimens/reference standards.
The 2 immunoblots containing the specimens with readily detectable CYP3A5 were developed for CYP3A5 then villin as described above for the individual specimens/reference strips, but the blots were not stripped.
Stripping of Immunoblots.
After sitting at room temperature for 1 hour, the reference strips and/or immunoblots containing the individual or pooled specimens were submerged in 400 mL stripping buffer (2% sodium dodecyl sulfate, 100 mM 2-mercaptoethanol, 62.5 mM Tris•HCl; pH, 6.7) in a glass pan, which was placed in a shaking water bath at 70°C. After 30 minutes, the blots were rinsed twice with large volumes (~300 mL) of PBS-T then developed for CYP3A4 and villin as described under Immunoblot development. Stripped blots incubated with the appropriate secondary antibodies showed that the anti-P-gp and -CYP3A5 primary antibodies were effectively removed (not shown). Preliminary studies indicated that the stripping procedure diminished the detection of CYP3A4 (but not villin) protein, although consistently, by 40-50% (hence relative CYP3A4 content would remain unchanged).
This article has not been copyedited and formatted. The final version may differ from this version. The calibration curves were used to convert IODs obtained for the study (and control) specimens to protein equivalents (or PE, in µ g). For each of the study and control specimens, the triplicate PE values obtained for P-gp, CYP3A4, CYP3A5, and villin were averaged.
Relative P-gp, CYP3A4, or CYP3A5 content was calculated as the ratio of the average P-gp, CYP3A4, or CYP3A5 PE to the average villin PE (designated as the PE ratio). Finally, the Pgp, CYP3A4, or CYP3A5 PE ratio was normalized to that obtained for the control specimen, which was set to a value of 1.00.
For the 1 immunoblot containing the triplicate sets of the 2 pooled homogenates (1 consisting of specimens from the men and 1 from specimens from the women), because reference standards and a control specimen were not used (nor needed), relative P-gp or CYP3A4 content was calculated as the ratio of the IOD of P-gp or CYP3A4 to that of villin. For the 2 immunoblots containing the CYP3A5-expressing specimens, because reference standards were not used (nor needed), relative CYP3A5 content was calculated as the ratio of the IOD of CYP3A5 to that of villin. The CYP3A5/villin IOD ratio was then normalized to that of the control specimen, which was set to a value of 1.00.
Statistical Analysis
The distributions of the data sets were assessed by the Kolmogorov-Smirnov test. The comparison of men and women with respect to mean duodenal P-gp (log 10 scale) and CYP3A4
relative content used 95% confidence intervals and two-sided t-tests (each with significance level α = 0.05). 
RESULTS
Consistency of the Methodology. For each protein analyzed (P-gp, CYP3A4, and CYP3A5, and villin), the band intensities were qualitatively similar among each set of triplicate immunoblots (Figure 1 ). With the study specimens, the coefficients of variation of the triplicate PE values for P-gp, CYP3A4, CYP3A5, and villin were virtually identical, with an average ± SD of 26 ± 15%, 27 ± 14%, 26 ± 16%, and 24 ± 16%, respectively. These systematic variations These variations appeared minimal, however, as the same statistical outcomes ensued if "nonnormalized" PE ratios (i.e., not normalized to the PE ratio of the control specimen) were used, further demonstrating the robustness of the results.
Variation in Relative Duodenal CYP3A4 Protein and P-gp Expression.
For specimens from 2 of the Caucasian men, all protein bands were too faint to produce reliable IODs. Similarly, for a specimen from 1 of the East Indian men, the CYP3A4 protein band was too faint to produce a reliable IOD. As such, meaningful relative CYP3A4 and P-gp expression values (i.e., PE ratios) were obtained for 90 and 91, respectively, out of the original 93 specimens.
Among all specimens, relative duodenal CYP3A4 and P-gp expression values varied 8-and 10-fold, respectively. The relative CYP3A4 values followed a normal distribution. The relative P-gp values did not follow a normal distribution and therefore required log This article has not been copyedited and formatted. The final version may differ from this version. transformation prior to applying the parametric statistical tests. For both CYP3A4 (PE ratio scale) and P-gp (log 10 PE ratio scale), the distribution of values for the men was similar to that for the women in terms of mean, median, minimum, maximum, interquartile range, and standard deviation (Figure 2) . A comparison of the standard deviation for the men to that for the women showed no sex difference for CYP3A4 (p = 0.23) or for log 10 P-gp (p = 0.26).
Likewise, a sex difference was not detected between mean CYP3A4 or log 10 P-gp (Table 2) .
Consistent with this result, a sex difference was not detected in the median CYP3A4 or P-gp values ( Table 2 ).
The lack of sex differences in mean and median relative CYP3A4 and (log 10 ) P-gp expression values determined with the 90 (or 91) individual subjects was confirmed when the pooled preparation containing specimens obtained from men was compared with that from women ( Figure 3) . A difference was not detected between the average (± SD) of the 3 CYP3A4/villin IOD ratios determined for the men (0.98 ± 0.05) and that for the women (1.01 ± 0.04) (p = 0.34). Similarly, a difference was not detected between the average (± SD) of the 3 P-gp/villin IOD ratios determined for the men (1.00 ± 0.07) and for the women (1.14 ± 0.08) (p = 0.08).
Secondary investigations included comparison of men and women within the sufficiently large subgroups. Restricting analysis to the subjects self-identified as Caucasian or to the CYP3A5 non-expressors had negligible effects on the comparisons of interest (Table 2) .
Restricting comparison to subjects younger than 45 years of age, thereby omitting 3 men and the 24 post-menopausal women, had minimal effect except for a small increase in mean and median relative CYP3A4 content for the women (Table 2 ). Sex differences in means, medians, and standard deviations were not detected in any of these subgroup analyses (Table 2) .
Whereas the uneven age distributions in both men and women precluded evaluation of the effect of age on duodenal CYP3A4 and P-gp expression, the relatively even proportions of pre-and post-menopausal women allowed comparison of these two subgroups. The mean relative CYP3A4 content in pre-menopausal women was 1.05 (Table 2 ) compared to a mean of 0.82 in the post-menopausal women (p = 0.01). Similarly, the median CYP3A4 contents for the pre-and post-menopausal women were 1.01 (Table 2) 
Frequency and Variation in Relative Duodenal CYP3A5 Protein Expression. The frequency of readily detectable immunoreactive CYP3A5 protein was 27% in this predominately
Caucasian group of individuals (Table 3) . A sex difference in this frequency (30% for men vs. 
DISCUSSION
The frequent reports of a higher systemic clearance of some CYP3A4 drug substrates in women compared to men are consistent with the recent demonstration that women express higher hepatic CYP3A4 specific content compared to men (Wolbold et al., 2003) . In contrast to systemic clearance, sex differences in the apparent oral clearance of CYP3A4 substrates have generally not been reported (Cummins et al., 2002) . This raised the possibility that a sexdependent expression of CYP3A4 exists in the small intestine but in a pattern opposite to that in the liver. Our analysis of duodenal biopsies obtained from 91 healthy volunteers not receiving known inducers or inhibitors of CYP3A4 does not support this hypothesis, however, as exemplified by the very small estimate of the mean difference (0.002) between men and women. Assuming that the current specimens are representative of healthy adult Americans, the 95% confidence interval for this difference, [-0.14, 0.14], implies that the probability that duodenal CYP3A4 content in men and women differ by more than ~15% is <5%. Although catalytic activities were not measured in the current study (due to insufficient material), it is reasonable to assume that a large sex difference also does not exist in duodenal CYP3A4 activity, as evidenced by a strong correlation between duodenal protein content and activity (r ≥ 0.84, p < 0.001) (Lown et al., 1994; Paine et al., 1997) . Opposing effects of sex differences in hepatic and intestinal CYP3A4 activity are therefore unlikely mechanisms underlying the general paucity of reported sex differences in the oral clearance of CYP3A4 substrates.
It should be noted that diets were not strictly controlled in many of these subjects.
Ingestion of juice prepared from some citrus fruits (e.g., grapefruit, Seville orange) has been shown to markedly reduce enterocyte CYP3A4 content Edwards et al., 1999) . It is therefore possible that interindividual differences in dietary habits resulted in changes in enterocyte CYP3A4 content that partially masked a true sex-related difference.
This article has not been copyedited and formatted. The final version may differ from this version. However, all subjects were fasted overnight prior to the endoscopic biopsy procedure, and the dietary habits of these individuals should otherwise represent a typical American population.
In rats, while sex differences in intestinal CYP expression are not evident (at the mRNA level) (Lindell et al., 2003) , differences in hepatic CYP expression are well established (Agrawal and Shapiro, 2001; Ahluwalia et al., 2004) . The differences in hepatic expression appear not to be the direct effect of sex hormones on the liver, but to sex differences in the time-dependent pattern of circulating growth hormone (GH) concentration (Agrawal and Shapiro, 2001; Ahluwalia et al., 2004) . A sex difference in circulating GH has also been reported in humans, and a previous study involving patients without anterior pituitary function demonstrated that the pattern of circulating GH could influence hepatic CYP3A4 activity (Jaffe et al., 2002) . The sex difference in CYP3A4 expression in human liver may therefore reflect in part GH secretion patterns. Although enterocytes contain the GH receptor, it was recently reported that post receptor binding events are not the same in hepatocytes and enterocytes (Dahly et al., 2004) .
Regardless of the mechanisms underlying the sex difference in CYP3A4 expression in the human liver, our observation of the lack of a difference in the duodenal biopsy specimens indicates such mechanisms are not operative at the level of the proximal small intestinal mucosa.
The clinical relevance of the 20% lower mean duodenal CYP3A4 content in post-vs.
pre-menopausal women is unclear. None of the women in the post-menopausal group was on hormone replacement therapy, and none of the women in the pre-menopausal group was taking birth control pills (or any other medications known to influence CYP3A4 expression) at the time the baseline biopsies were obtained. To our knowledge, menopausal status has not been reported to influence the apparent oral clearance of CYP3A4 substrates; at least one study designed to address this issue did not detect such an effect (Gorski et al., 2000) . This may reflect the relatively small difference observed between pre-and post-menopausal women in the current study combined with the reported lack of a difference in hepatic CYP3A4 expression between the two groups (Wolbold et al., 2003) .
The polymorphic CYP3A5, which shares many of the same substrates as CYP3A4, was readily detected in 23% of the specimens obtained from the individuals self-identified as
Caucasian. This is consistent with earlier findings involving liver microsomal preparations obtained from American Caucasian individuals (23%) (Lin et al., 2002) . These higher frequencies compared to that reported by Wolbold et al. (8.5%) , whose liver specimens were obtained from European Caucasians, likely reflected the greater genetic diversity in the American groups. Interindividual variation in expression levels, however, was in good agreement among all 3 groups (7 to 13-fold) (Lin et al., 2002; Wolbold et al., 2003) . Finally, consistent with an earlier report regarding hepatic CYP3A5 (Wrighton et al., 1990 ), a sex difference was not detected in CYP3A5 content in the current group of duodenal specimens.
In accord with the study by Wolbold et al. (2003) , where median hepatic P-gp levels did not significantly differ between men and women, a sex difference also was not evident for this transporter in the current duodenal specimens. Together, these results do not support the hypothesis (Cummins et al., 2002 ) that sex differences in the oral clearance of dual CYP3A4/Pgp substrates can be attributed to higher P-gp expression in men compared to women.
In summary, this work represents the largest number of specimens examined to date to determine whether sex influences expression levels of CYP3A4 or P-gp in the upper small intestine. The lack of evidence of a sex difference in intestinal P-gp expression is consistent with the reported lack of a difference in hepatic P-gp expression. The absence of a substantial sex difference in CYP3A4 expression in the intestine, unlike in the liver, further supports the contention that the enzyme is regulated by different mechanisms in the 2 organs. The lack of a sex-related difference in intestinal CYP3A4 could account in part for the paucity of reported sex differences in the oral, relative to systemic, clearance of certain CYP3A4 substrates. The This article has not been copyedited and formatted. The final version may differ from this version. 
